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Molecular genetics of MHC class II alleles in Chinese patients
with IgA nephropathy
PHILIP KAM TAO LI, ANGELA S.Y. PooN, and KAR NENG LAI
Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong
Molecular genetics of MHC class II alleles in Chinese patients with IgA
nephropathy. We have studied the restriction fragment length polymor-
phism (RFLP) of the major histocompatibility complex (MHC) class II
DQ and DR regions of 79 Chinese patients with IgA nephropathy
(IgAN) and compared it with 104 normal Chinese controls. The DR and
DQ alleles were confirmed by polymerase chain reaction using se-
quence specific primers. There was a significantly higher frequency of
homozygous DQ/33b (DQ7) in patients with IgAN (16.4%) compared
with controls (5.7%). Seventy-one IgAN patients had their renal biop-
sies graded according to histopathological severity: grades I, II or III.
There was no statistical difference in the DR and DQ alleles among the
three grades. Seventy-three patients were classified into group A with
normal and stable renal function (serum creatinine 150 .&mo1/liter)
and group B with chronic renal failure (serum creatinine > 150
tLmollhter). There was a significant increase in frequency of DQA2 U
(DXa U) allele in group B (66.9%) compared with group A (26.9%).
Also, there was an increased frequency of DQa2 allele in the group A
(40.4%) compared with group B (14.3%). Out of the 24 patients carrying
the DQa2 allele, 17 were DQA2 U allele-negative and they all had
normal renal function, suggesting that DQA2 U allele is associated with
a poor prognostic factor in IgAN. The study shows that DQ alleles are
probably the important genetic loci or are close markers for the disease
susceptibility and prognostic index for IgAN in Chinese people.
IgA nephropathy (IgAN) is the most common primary gb-
merulonephritis in the world [1] and it accounts for 35% of all
primary glomerulonephritis in Chinese people living in Hong
Kong [2]. Although the exact pathogenesis of IgAN is un-
known, patients with IgAN have disturbances of cellular and
humoral immunity with altered cytokine production [3, 4].
Hyperactivity of T helper cells, selective increase of IL-2,
interferon-gamma production, and an increase in IL-2 receptor
and IL-4 receptor expressions are found in IgAN [3]. Anti-
mesangial cell antibodies were detected in IgAN and an auto-
immune nature of the disease was suggested [5]. Heredity plays
an important role in IgAN as familial cases of IgAN are well
documented in Chinese, Caucasians and Japanese [6—9].IgAN
was previously reported to be associated with HLA DR4 in
Japanese and DQw7 in Caucasians [9, 10]. Major histocompat-
ibility complex (MHC) class II molecules are important in the
immune-mediated T helper cell activity and the cytokine re-
sponses in autoimmunity [11]. Thus, MHC is probably involved
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with the immunopathogenesis of IgAN. With the use of restric-
tion fragment length polymorphism, we studied the MHC class
II antigen in a group of Chinese IgAN patients, and also
examined any possible effect of the MHC class II genes on the
histopathological severity and prognosis of IgAN.
Methods
Patients
Seventy-nine unrelated Chinese patients with primary IgAN
were studied. IgAN was defined as mesangial proliferative
glomerulonephntis with predominant IgA deposits in the me-
sangium. Systemic lupus erythematosus, Henoch-Schönlein
purpura or liver cirrhosis were excluded by detailed clinical
examination and negative serology.
The histopathology of the renal biopsy of the patients was
reviewed and classified into grade I, II or III as previously
described [2, 12]. In essence, grade I denoted the presence of
mild mesangial proliferation (cells, matrix or both) without
tubulointerstitial changes. Grade 2 indicated moderate degree
of mesangial proliferation and increase in matrix, occasional
areas of glomerular sclerosis and crescent formation (in <20%
of the gbomeruli) and 5 to 15% of interstitial changes. Grade 3
denoted the presence of grade 2 findings but with more than
30% gbomerular sclerosis and 15% interstitial changes.
The IgAN patients were also divided into two groups accord-
ing to their renal function. Group A comprised those with stable
renal function with serum creatinine persistently less than 150
molIliter for at least 12 months. Group B comprised patients
with chronic renal failure, and their latest serum creatinine
exceeded 150 molIliter.
Controls
One hundred and four normal, unrelated Chinese individuals
acted as controls.
DNA -RFLP analysis
Genomic DNA was extracted from peripheral blood leuko-
cytes of all 79 IgAN patients and 104 normal controls by
standard techniques. Ten micrograms of this DNA were di-
gested to completion with the restriction endonuclease Taq I
(Amersham, UK). Fragments were separated by gel electro-
phoresis in 0.7% agarose gels, denatured and transferred to
nylon membranes (Hybond N, Amersham, UK) by vacuum
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[13]. The membranes were hybridized sequentially with radio-
labeled cDNA probes to the DRB, DQB and DQA genes as
previously described [10].
Genotyping using polymerase chain reaction (PCR) and
sequence spec j/ic primers (SSP)
The genotypes of the samples were confirmed with PCR SSP
using primers for DRB 1 and DQB1 alleles provided by Dr. 0.
Olerup [14, 15]. The primers were according to published data
for the DRB and DQB alleles recognized by the HLA Nomen-
clature Committee in November 1991 [16]. The DR primers can
type all the DR1 to DR18 including DR'Br'. The sequences of
the primers, the PCR reactions and visualization of PCR
products were as published [14, 15, 17, 18].
Nomenclature
The nomenclature of RFLP is primarily based on the classi-
fication of RFLP according to Bidwell [17]. The types are
prefixed with a and 3 to indicate that these assignments were
obtained by DNA analysis. There are subtypes in DR/3 which
are found in Chinese people which have been recently de-
scribed [18].
The nomenclature of the PCR SSP typing is based on the
HLA Nomenclature Committee in November 1991 [16].
Statistics
The significance of association was tested using the chi
square test. The probability of an HLA association was cor-
rected for the number of comparisons made by multiplying the
P values obtained by the number of different haplotypes in the
control group of the 104 Chinese individuals.
Results
Allogenotype frequencies
RFLPs generated by the DRf, DQa and DQI3 probes could
accurately assign most of the DR and DQ alleles in our control
Chinese subjects [17]. We were able to assign DR/3, DQa and
DQ/3 alleles to the patients with IgAN. The various frequencies
are listed in Table 1. There was no significant difference
between the control and the IgAN patients in the DQa, DQI3
and DR/3 alleles. DQw7 (DQf33b) which was found to be
increased in IgAN Caucasoid patients was increased in this
study's group of Chinese patients (IgAN 58.2% vs. control
47.1%), but the difference was not statistically significant.
DQA2 U allele was increased in IgAN patients (40.5%) com-
pared with controls (28.1%) but was also not statistically
significant.
We recently reported a family of IgAN in three siblings who
all share a common haplotype: homozygous DR12, DQw7 and
DQalb [6]. Thus we analyzed the IgAN patients and the
controls for the presence of homozygosity of the various
allogenotypes. There was an increased frequency of homozy-
gous DQ/33b (DQw7) (16.4%; 13 of 79) compared with control
(5.7%; 6 of 104) ( 6, P = 0.015). By PCR and SSP typing,
the DQJ3 3b (DQw7) were confirmed to be the DQB1*0301/4,
using primers from Dr. Olerup [14, 15]. There was no significant
difference between the other homozygous HLA alleles in the
IgAN and the controls (data not shown).
Table 1. Frequency of HLA DRI3, DQa and DQI3 antigens in IgA
nephropathy patients and controls
Patients
N=79
% N
Controls
N=104
% N
DRI3 allele
1 2.5 2 0 0
2 25.3 20 34.6 36
3 7.6 6 8.6 9
4 30.4 24 24 25
5(wIl,wl2) 67 53 48 50
6 (w13,w14) 12.6 10 16.3 17
7 6.4 5 9.6 10
8 10.1 8 5.7 6
9 21.5 17 29.8 31
10 3.8 3 7.7 8
DQa allele
Ia 18.9 15 22.1 23
lb 60.7 48 61.5 64
ic 11.4 9 7.7 8
2 32.9 26 20.2 21
3 54.4 43 58.7 61
DXa allele (DQA2)
L 89.9 71 94.8 91
U 40.5 32 28.1 27
DQJ3 allele
la 32.9 26 37.5 39
lb 6.3 5 11.5 12
2a 7.6 6 8.6 9
2b 16.4 13 22.1 23
3a 45.6 36 51 53
3b (DQw7) 58.2 46 47.1 49
a Not significant
The IgAN patients were further divided into the groups
having grade I, II or III pathology. Only 71 biopsies could be
reviewed for histological grading. Table 2 shows the distribu-
tion of the DQa, DQ3 and DR patterns in these three groups
of patients. There were 32 patients (45.1%) with grade I, 28
(39.4%) with grade II and 11(15.5%) with grade III histopathol-
ogy. There was no statistical difference in the HLA genotype
frequencies among the three groups of patients with regard to
their histopathological grading of IgAN. It is noted that more
grade III IgAN patients were DQA2 allele-positive (54.5%)
compared with grade I or II patients (Table 2). However, as the
number of patients with grade III histology is small, it is
statistically not significant.
Among the 79 IgAN patients, 6 patients were lost to fol-
low-up and their latest renal function could not be recorded. Of
the remaining 73 patients analyzed, 52 patients (71.3%) had
stable renal function (group A) while 21 patients (28.7%) had
renal impairment with serum creatinine> 150 molIliter (group
B). Group A had 17 males and 35 females with a mean age of
32.8 years (range 18 to 67 years). Their mean duration of
follow-up after renal biopsy was 58.4 months (range 12 to 106
months). There were 9 males and 12 females in group B with a
mean age of 35.9 years (range 24 to 54 years). The mean
duration of follow-up after diagnosis was 57 months (range 14 to
94 months). There was no significant difference between group
A and group B in their age and the duration of clinical illness.
Table 3 shows the distribution of HLA allogenotypes in the
two groups of patients. HLA DQa2 was found to be signifi-
cantly lower in group B with chronic renal failure (14.3%)
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Table 2. Distribution of HLA allogenotypes in the three histological
gradings of 71 IgA nephropathy patients
Grade I
(N = 32)
Grade II
(N = 28)
Grade III
(N = 11)
%
DR(3 allele
1 0 0 9.1
2 18.8 25 54.5
3 12.5 3.6 0
4 34.4 35.7 18.2
5(11,12) 71.8 71.4 54.5
6(13,14) 12.5 7.1 9.1
7 3.1 3.6 9.1
8 6.3 10.7 18.2
9 25 25 9.1
10 9.4 0 0
DQa allele
Ia 18.8 10.7 18.2
lb 62.5 57.1 72.7
lc 6.3 14.3 18.2
2 37.5 32.1 27.3
3 59.3 60.7 45.4
DXa allele (DQA2)
L 90.6 85.7 90.9
U 37.5 35.7 54.5
DQ/3 allele
la (DQwS) 28.1 25 45.4
lb (DQw6) 6.3 3.6 18.2
2a 12.5 3.6 0
2b 9.4 14.3 36.4
3a 53.1 50 27.3
3b (DQw7) 56.2 67.9 45.4
There was no statistical difference among the 3 grades of pathology
with regard to HLA typing.
compared with group A with normal renal function (40.4%) (x2
= 4.62, P < 0.05). On the other hand, DQA2 U allele (previ-
ously known as DXa U allele) was found to be significantly
higher in group B with chronic renal failure (66.7%) compared
with group A (26.9%) ( = 9.9, P < 0.004).
The comparison of frequency of DQA2 U (upper) fragment
between this subgroup with chronic renal failure (66.7%) and
the 104 normal controls (28.1%) was highly significant (x2 =
13.1; P < 0.0003; relative risk = 5.43).
Thirty IgAN patients were DQA2 U allele-positive and three
of them (10%) had end-stage renal failure requiring dialysis.
Forty-three patients were DQA2 U allele-negative and one
(2.3%) required dialysis. The renal function of the IgAN pa-
tients not on dialysis was analyzed. The mean serum creatinine
of the DQA2 U allele-positive group [251 46 mol/liter (mean
SEM)] was significantly higher than the DQA2 U allele-
negative group (113 12 molJliter; P < 0.01). Thus, DQA2 U
allele-positive patients were more likely to develop end-stage
renal failure requiring dialysis and their renal function was
worse than the DQA2 U allele-negative group.
Altogether, there were 24 IgAN patients who were positive
for DQa2 allele. When this subgroup was analyzed further, we
found that all the 17 DQA2 U allele-negative patients were in
group A with normal renal function (Table 4). Only 3 out of
these 24 (12.5%) DQa2 positive patients had renal failure (group
B) and they were all DQA2 U allele-positive. However, four
patients who were positive for DQA2 U allele but also positive
for DQa2 had normal renal function (group A) (y 8.33; P =
Table 3. Distribution of HLA allogenotypes in 73 IgA patients
classified according to stable (group A) and impaired renal function
(group B)
Group A
Cr < 150 mol/liter(N=52)
C
Group B
r> 150 imol/liter
(N=21)
%
DR/3 allele
1 0 4.8
2 25 28.6
3 7.7 4.8
4 28.8 38
5(11,12) 75 52.4
6 (13,14) 9.6 14.3
7 3.8 9.5
8 5.8 19
9 23 23.8
10 5.8 0
DQa allele
la 13.5 23.8
lb 61.5 61.9
lc 7.7 19
2 40.4 l4.3a
3 50 66.7
DXa allele (DQA2)
L 92.3 80.9
U 26.9 667b
DQt3 allele
la (DQw5) 28.8 33.3
lb(DQw6) 5.8 9.5
2a 7.7 4.8
2b 11.5 23.8
3a 69.2 57.1
3b (DQw7) 63.5 47.6
a
= 4.62, P = 0.0318b 9.9, P = 0.0016
Table 4. Distribution of DQA2 U allele into stable renal function
(group A) and renal failure group (group B) among the 24 DQa2-
positive IgAN patients
seru
15
Group A
m creatinine
0 &mol/liter
seru
> 15
Group B
m creatinine
0 molIliter
DQA2U+ve 4 3
DQA2 U —ye 17 0
x2 = 8.33, P < 0.005.
0.0039). Figure 1 shows a representative blot of RFLP of DQA2
alleles in six IgAN patients. Patients 13, 16, 25 and 26 had
homozygous DQA2 L alleles at 2.1 Kb. Patients 23 and 24 were
heterozygous for DQA2 with additional upper allele (U) at 2.2
Kb. Patients 16, 25 and 26 had normal renal function with serum
creatinine of 79, 92 and 77 molJliter, respectively. Patient 23
was in end-stage renal failure on dialysis. Patient 24 had a serum
creatinine of 505 prnollliter. Patient 13 was lost to follow-up and
the latest renal function was not available.
Discussion
MHC had been studied previously in the association with
IgAN in various ethnic groups and it has been found to be
associated with HLA-DR4 in Japanese and DQw7 in Cauca-
sians [9, 10, 19]. There were few studies undertaken in Chinese
.0
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Fig. 1. A representative blot showing DQcr hybridization. The 2.2 Kb
fragment is the DQA2 U allele and 2.1 Kb DQA2 L allele. Patients 16,
25 and 26 are homozygous for DQA2 L allele and have normal renal
function. Patients 23 and 24 are heterozygous for DQA2 U and L allele
and have renal failure. Patient 13 is lost for follow-up.
to study the association between MHC and IgAN [20, 21].
Chan, Ku and Sinniah [20] and Huang et al [21] could not find
any association between HLA and IgAN. However, these two
studies used conventional serological typing, and Chan, Ku and
Sinniah [20] only studied HLA-A and -B locus. It is now clear
that genetic analysis of the HLA system would reveal greater
polymorphism than was apparent serologically and such geno-
typing method can facilitate the study of the association of HLA
class II genes with autoimmune diseases.
From our previous study, the RFLP analysis in the Chinese
correlates very well with DR serology and it showed more
polymorphisms. The genotyping results by RFLP were con-
firmed by polymerase chain reaction using sequence specific
primers [18]. Our study shows that RFLP can accurately
genotype the 79 IgAN patients.
DQw7 which was found to be associated with IgAN in
Caucasians was not significantly increased in the Chinese. By
RFLP, DQw7 is the same as DQ/33b. This was confirmed by our
previous and the present study using the PCR and SSP typing to
be DQB 1*0301/4 according to the HLA Nomenclature Commit-
tee in 1991 [16, 18].
We recently reported a Chinese family with IgAN where the
disease was associated with homozygous DRw12, DQw7 and
DQalb [6]. Our present study also showed a higher incidence of
homozygous DQ/33b (DQw7) when compared with control.
While there was an increase in frequency in homozygous
DQ/33b, there was no significant difference in homozygous
DR12, DQalb, or any other DR and DQ alleles. The importance
of homozygosity of an HLA allele in IgAN had never been
studied. However, in other immune-mediated diseases like
insulin-dependent diabetes mellitus (IDDM), a recessive inher-
itance has been well documented. In a study of a number of
IDDM families, Rubinstein, Suciu-Foca and Nicholson [22]
demonstrated that IDDM was inherited as a recessive trait with
a penetrance of 50%. Todd, Bell and McDevitt [23] had found
the HLA DQ gene susceptibility in patients with IDDM. Full
HLA susceptibility to IDDM is dependent on the individual
having two Asp-57-negative DQI3 alleles. If an individual carries
one Asp-57-negative and one Asp-57-positive allele, that person
has a much lower risk of developing IDDM [23]. A double dose
effect of the MHC class II genes may exist, possibly as
homozygous HLA-DQ/33b alleles on the Chinese IgAN pa-
tients.
Recently, Rambausek, Waldherr and Ritz [24] studied 67
Caucasian IgAN patients and compared with 101 controls. They
found that DQala was significantly increased (43.3%) com-
pared with control (22.8%). Moore [25] studied the HLA-DP
loci in IgAN in three European populations (British, Italian and
Finnish) and found no association. However, that study con-
firmed his previous finding that IgAN was associated with the
HLA DQ loci [25].
HLA complex could influence the severity of nephritis, its
tendency to relapse, or the likelihood of progression to renal
failure [19, 26, 27]. With respect to IgAN, Berthoux Ct al [26]
found that HLA B35 is associated with poor prognosis. Hiki et
al [27] initially found that the presence of HLA B35 and HLA
DR4 inferred good prognosis, while in their follow-up study
they could not confirm such association [281.
Our study found that IgAN with chronic renal failure (group
B) had a higher frequency of HLA DQA2 U fragment (66.6%)
compared with the group A having normal renal function
(26.8%). Compared with normal controls, the relative risk of
developing impaired renal function with DQA2 U fragment is
5.43. DQA2 is part of the MHC that has DQA2 U (upper) and
DQA2 L (lower) polymorphism which can be detected by DQa
probe. These were previously designated as DXa U and DXa L
[161. This allelic polymorphism has been associated with IDDM
[29], Grave's disease [30] and multiple sclerosis [31]. DQA2 U
fragment was reported to be associated with IDDM [29]. On the
other hand, DQA2 L allele correlated with reduced susceptibil-
ity to multiple sclerosis [31]. There was a strong correlation
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between the DQA2 U allele and the outcome of Grave's disease
such that a much higher frequency of relapse occurred in
patients with the DQA2 U allele. However, from the literature
review, there were no reports studying the association between
DQA2 alleles with any renal diseases or hypertension. Our
study found that DQA2 U allele was not associated with disease
susceptibility to IgAN (Table 1). However, IgAN patients with
DQA2 U allele are more likely to go into renal failure. DQA2
alleles are DQa-chain-related sequence which were previously
not known to be expressed [16]. However, recently, the exis-
tence of spliced DQA2 mRNA was demonstrated in human B
lymphoblastoid cell lines suggesting that the DQA2 gene may be
expressed [32]. One postulation is that the presence of DQA2 U
allele in association with a particular HLA allogenotypes in
IgAN may lead to a more severe disease possibly by providing
a greater variety of antigen binding sites [30]. The DQA2 U
allele may be a gene that affects the disease activity, producing
a product that is important in disease progression. Indeed,
IgAN patients were different in their disease severity and
progression [2]. Genetic predisposition may be one of the
variables that determine such effect. Recently, Moore [25] also
described that in his study of Caucasian IgAN patients renal
impairment was associated with a DQA1 RFLP's in the Italian
subjects. The median serum creatinine was decreased in the 5.5
Kb-negative subjects compared with 5.5 Kb-positive subjects.
On the other hand, the serum creatinine was increased in 4.6
Kb-positive subjects compared with 4.6 Kb-negative IgAN
subjects [25]; 4.6 Kb is probably DQa 2 and 5.5 Kb is probably
DQa 3 in the classification according to Bidwell [17] (Fig. 1).
It is interesting to note that in our study, group A patients
with normal renal function had a significantly higher frequency
of DQa 2 which is different from the results reported by Moore
on the Italian IgAN patients [25]. Such a discrepancy in the
different ethnic groups in the association of DQA allele with the
prognosis of the IgAN can be explained by the different disease
susceptibility gene operating in different ethnic groups. The
different DQ genes associated in the various ethnic groups
could lead to a similar conformation of the antigen binding site
resulting in final common pathway with regard to antigen
interaction. In the Chinese, the association of homozygous
DQw7 (DQf33b) with IgAN and DQA2 U allele with a worse
prognostic group is consistent with the fact that HLA DQ locus
may be the important locus for determining susceptibility to
autoimmunity or it is a closer marker to the actual susceptibility
gene [10, 24, 25]. In fact, HLA-DQ antigen has been found to be
involved in T cell recognition, as candidate immune response
and immune suppression gene in their association with autoim-
mune diseases [33]. The critical event in the development of an
immune response is presentation of antigen to helper T lym-
phocytes, and it is this that is probably responsible for discrim-
ination of sell from foreign antigen. Processed antigen is re-
expressed on the cell surface bound to a MHC molecule [34]. T
cell receptors can only recognize antigenic peptides bound to
MHC molecules. The recently discovered three-dimensional
structure of the MHC class II molecules was very similar to
MHC class I molecules and has highly polymorphic domains
which form an antigen-binding groove [35]. Amino acid changes
can alter the three-dimensional conformation of the groove and
hence the range of antigenic peptides that it can bind [36]. This
is believed to be the basis of the allele-specific effects which
define the "immune response genes" that are responsible for
many of the MHC associated influences on immunity. This is
probably important in the immunopathogenesis of IgAN.
Yokoyama et al [37] had demonstrated the presence of
glomerular expression of HLA-DQ in 51% of Japanese patients
with IgAN but not in normal controls. There was a close
association between serum gamma interferon levels and gb-
merular HLA-DQ expression and acute exacerbations of dis-
ease in these IgAN patients suggesting the potential importance
of HLA-DQ alleles in the disease [37]. IgAN in different
populations have different prevalence, disease progression and
prognosis [1, 2, 38]. This may be part of the reason for the
difference in MHC susceptibility in IgAN in various ethnic
groups.
In our study, we could not find any relationship between
HLA DR or DQ locus with the histopathobogical grading of the
biopsy in the IgAN patients, despite the fact that IgAN with
renal failure is associated with DQA2 U allele. This is not
surprising as in IgAN, the initial pathological data from the
biopsy does not always have a good predictive value in the
prognosis of IgAN [38], although in general grade III histology
with severe glomerular sclerosis, interstitial fibrosis and tubular
atrophy will have the worst prognosis resulting in renal failure
[1, 2].
A more extensive study is required to confirm if DQA2 U
allele is associated with chronic renal failure in IgAN in the
Chinese. Such data are important in providing a prognostic
index for IgAN. At present, the treatment of IgAN is not
satisfactory as it is difficult to design a clinical trial in IgAN due
to its diversified prognosis and progression in different patients.
When the group of poor prognosis can be identified, it helps in
the selection of IgAN patients for a controlled trial of treatment.
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